TriVascular Merger (Tables)

6 Months Ended

Jun. 30, 2017

Business Combinations [Abstract]

Summary of Purchase Consideration Given in Acquisition

The total purchase consideration given related to the acquisition follows:

Cash consideration	$	84,634
Common stock consideration	100,812
Fair value of assumed TriVascular stock warrants	44
Total purchase consideration	$	185,490

Summary of Allocation of Purchase Consideration

The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 3, 2016 (in thousands):

Cash and cash equivalents	$	24,012
Short-term investments	3,008
Accounts receivable	5,780
Inventories	17,765
Prepaid expenses and other current assets	1,895
Property and equipment	3,152
Intangible assets	46,200
Other assets	317
Accounts payable	(2,214		)
Accrued liabilities and other	(6,450		)
Notes payable	(61		)
Net assets acquired	$	93,404
Goodwill	$	92,086
Total purchase consideration	$	185,490

Summary of Pro Forma Financial Information of Acquisition

The following unaudited pro forma combined financial information summarizes the results of operations for the period indicated as if the TriVascular merger had been completed as of January 1, 2015. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect, among other things, the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of January 1, 2015 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

	Three Months Ended			Six Months Ended
	June 30, 2016			June 30, 2016
Combined net sales	$	50,974		$	96,011
Combined net loss from continuing operations	(62,507		)	(110,730		)
Combined basic and diluted net loss per share	$	(0.76	)	$	(1.35	)